posted on 2013-11-27, 00:00authored byJin Wen Bin, Iris L. K. Wong, Xuesen Hu, Zhang Xiao Yu, Li Fu Xing, Tao Jiang, Larry M. C. Chow, Wan Sheng Biao
A novel
series of permethyl ningalin B analogues were synthesized
and evaluated for their P-glycoprotein (P-gp)-modulating activities
in a P-gp-overexpressing breast cancer cell line (LCC6MDR). Compounds 35 and 37, which possess one methoxy group and
one benzyloxy group at aryl ring C, displayed the most potent P-gp-modulating
activity. A 1 μM concentration of 35 and 37 resensitized LCC6MDR cells toward paclitaxel by 42.7-fold,
with respective EC50 values of 93.5 and 110.0 nM. Their
mechanism of P-gp modulation is associated with an increase in intracellular
drug accumulation. Their advantages also include low cytotoxicity
(IC50 for L929 fibroblast >100 μM) and high therapeutic
indexes (>909 after normalization with their EC50 values). 35 is not a substrate of P-gp. They are potentially dual-selective
modulators for both P-gp and breast cancer resistance protein transporters.
The present study demonstrates that these new compounds can be employed
as effective and safe modulators of P-gp-mediated drug resistance
in cancer cells.